Prime Medicine (PRME) Competitors $1.32 -0.01 (-0.75%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.36 +0.03 (+2.65%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PRME vs. XERS, NTLA, EOLS, AVDL, CRON, PRAX, OCS, CDXC, NUVB, and ABCLShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Xeris Biopharma (XERS), Intellia Therapeutics (NTLA), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), Praxis Precision Medicines (PRAX), Oculis (OCS), ChromaDex (CDXC), Nuvation Bio (NUVB), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Xeris Biopharma Intellia Therapeutics Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Oculis ChromaDex Nuvation Bio AbCellera Biologics Prime Medicine (NYSE:PRME) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Which has preferable valuation and earnings, PRME or XERS? Xeris Biopharma has higher revenue and earnings than Prime Medicine. Xeris Biopharma is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$2.98M58.04-$198.13M-$1.65-0.80Xeris Biopharma$203.07M3.32-$62.26M-$0.38-11.53 Do analysts rate PRME or XERS? Prime Medicine presently has a consensus target price of $13.38, suggesting a potential upside of 913.26%. Xeris Biopharma has a consensus target price of $6.10, suggesting a potential upside of 39.27%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to PRME or XERS? In the previous week, Xeris Biopharma had 2 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Xeris Biopharma and 2 mentions for Prime Medicine. Xeris Biopharma's average media sentiment score of 1.13 beat Prime Medicine's score of 0.77 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, PRME or XERS? Prime Medicine has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Does the MarketBeat Community prefer PRME or XERS? Xeris Biopharma received 119 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 70.00% of users gave Xeris Biopharma an outperform vote while only 66.67% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes2866.67% Underperform Votes1433.33% Xeris BiopharmaOutperform Votes14770.00% Underperform Votes6330.00% Do insiders and institutionals have more ownership in PRME or XERS? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PRME or XERS more profitable? Prime Medicine has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Xeris Biopharma -33.69%N/A -17.38% SummaryPrime Medicine beats Xeris Biopharma on 10 of the 19 factors compared between the two stocks. Remove Ads Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$173.13M$2.90B$5.33B$18.52BDividend YieldN/A1.91%5.11%4.22%P/E Ratio-0.6431.0021.7231.15Price / Sales58.04441.16376.8825.69Price / CashN/A168.6838.1517.53Price / Book0.963.476.474.29Net Income-$198.13M-$72.06M$3.20B$1.02B7 Day Performance5.60%3.17%2.86%-0.79%1 Month Performance-26.26%-16.97%-8.55%-6.88%1 Year Performance-74.95%-29.07%10.58%1.74% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine2.7877 of 5 stars$1.32-0.8%$13.38+913.3%-75.7%$174.44M$2.98M-0.64234XERSXeris Biopharma4.3185 of 5 stars$4.41flat$6.10+38.3%+136.8%$678.88M$203.07M-9.80290Short Interest ↑News CoveragePositive NewsNTLAIntellia Therapeutics4.3276 of 5 stars$6.54-1.4%$37.56+474.2%-67.9%$677.00M$57.88M-1.20600High Trading VolumeEOLSEvolus3.5092 of 5 stars$10.24-4.2%$24.67+140.9%-14.0%$651.13M$266.27M-11.25170Analyst RevisionPositive NewsGap DownAVDLAvadel Pharmaceuticals2.2544 of 5 stars$6.69-1.6%$19.88+197.1%N/A$646.45M$169.12M-8.4770Analyst RevisionGap DownCRONCronos Group1.5759 of 5 stars$1.68-1.8%$3.00+78.6%-29.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9287 of 5 stars$31.53-3.4%$123.33+291.2%-44.4%$635.74M$8.55M-3.06110OCSOculis1.9829 of 5 stars$14.37-7.3%$29.50+105.3%+49.0%$627.42M$980,000.00-7.452High Trading VolumeCDXCChromaDex2.2758 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastNUVBNuvation Bio2.4722 of 5 stars$1.81+8.7%$8.75+384.8%-29.7%$611.32M$7.87M-0.8360Positive NewsHigh Trading VolumeABCLAbCellera Biologics2.1351 of 5 stars$2.05-1.9%$7.00+241.5%-41.9%$610.88M$28.83M-3.36500High Trading Volume Remove Ads Related Companies and Tools Related Companies Xeris Biopharma Alternatives Intellia Therapeutics Alternatives Evolus Alternatives Avadel Pharmaceuticals Alternatives Cronos Group Alternatives Praxis Precision Medicines Alternatives Oculis Alternatives ChromaDex Alternatives Nuvation Bio Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
